A comparing study of clarithromycin XL with co-amoxiclav for treatment of chronic sinusitis; a clinical trial

Chronic sinusitis is one of the most common medical problems affecting 30 million people in USA annually. In the present study, we compared the efficacy and safety of clarithromycin XL and co-amoxiclav on clinical and CT scan findings of patients suffering from chronic sinusitis.Patients and In this clinical trial, a total of 59 subjects (37 males and 22 females, mean age 28 years) with clinical symptoms and CT scan findings of chronic sinusitis were assigned randomly in two groups and treated with clarithromycin XL or co–amoxiclav. Clinical success rates were similar at the end of therapy period, however, subjects receiving clarithromycin XL showed better CT scan findings when compared with co-amoxiclav-treated subjects (53% versus 29%). Gastrointestinal discomfort was the most frequent treatment–related adverse effects in both groups (NS). Results revealed that clarithromycin XL and co-amoxiclav have similar efficacy when considered for treatment of chronic sinusitis.